Nike founder Philip H. Knight and his wife Penny have made a new $90 million gift to extend the work of the Knight Initiative For Brain Resilience at Stanford University’s Wu Tsai Neurosciences Institute
Gift advances research into brain resilience and aging
May 12, 2026
A $90 million gift from Penny and Phil Knight will extend the work of the Knight Initiative for Brain Resilience at Stanford’s Wu Tsai Neurosciences Institute
In pursuit of brain resilience
May 12, 2026
In this research roundup, we look back on some of the ways Knight Initiative scientists have been pursuing ways to keep our minds sharp well into old age
6 Common Medications That May Lower Your Dementia Risk
Apr 20, 2026
Shingles vaccines appear to have a protective benefit, Knight Initiative researcher Pascal Geldsetzer has shown.
What sea creatures reveal about how fast people age
Apr 6, 2026
Researchers who videotaped every moment in the lives of 81 African turquoise killfish gleaned intriguing insights into the aging process that may also apply to humans
Why women get Alzheimer’s more often than men
Apr 6, 2026
Stanford Medicine neurologists explain what is known—and still unknown—about the Alzheimer's gender gap
Scientists Map Aging Across the Body of a Short-Lived Fish
Apr 1, 2026
Knight Initiative researchers created a new atlas of aging in the killifish tracks how organs change over time, revealing processes implicated in Alzheimer’s and Parkinson’s diseases
New ideas in aging and resilience research launched by Rosenkranz Foundation and Knight Initiative
Mar 23, 2026
The Rosenkranz Aging and Rejuvenation Seed Grant Program announced eight innovative new research projects with additional support from the Knight Initiative for Brain Resilience
Just one day in your life could soon reveal how long you'll live
Mar 18, 2026
After building a Truman Show experiment, scientists were able to predict the lifespans of their 81 subjects
Study of pythons’ extreme diet reveals new hunger-curbing molecule
Mar 19, 2026
The snakes’ unique feeding behavior offers new clues about the gut-brain axis—and hints of a potential weight-loss drug with fewer side effects than GLP-1 drugs